Borealis Foods (NASDAQ: BRLS) is a food technology company dedicated to developing and commercializing plant-based and fermentation-derived ingredients for the global food and beverage industry. Headquartered in Cambridge, Massachusetts, the company leverages proprietary high-throughput fermentation processes to create sustainable, functional proteins and fats that serve as direct analogs to animal-derived ingredients. Since its founding in 2018, Borealis Foods has positioned itself at the intersection of food science and sustainability, aiming to reduce environmental impact while meeting evolving consumer tastes.
The company’s product portfolio spans a range of dairy, meat and seafood alternatives. Its flagship offerings include fermentation-derived whey and casein proteins for cheeses and yogurts, pea‐ and microalgae‐based proteins for high‐performance meat analogs, and structured plant oils designed to mimic the mouthfeel of animal fats. Through partnerships with leading consumer packaged goods (CPG) companies, foodservice operators and restaurant chains, Borealis Foods supplies both branded and private‐label customers seeking to enhance the nutritional profile and sensory quality of their plant‐based lines.
On the manufacturing front, Borealis Foods operates an integrated pilot facility in Massachusetts and collaborates with contract manufacturers in North America and Europe. This hybrid model enables the company to scale quickly while maintaining strict quality controls and minimizing capital requirements. Its distribution network spans the United States, Canada and select European markets, with plans to expand into Asia-Pacific by 2025. The company also works closely with ingredient distributors and co-manufacturers to ensure a steady supply of its fermentation-derived materials to downstream producers.
Led by Chief Executive Officer Dr. Melanie Rivera, Borealis Foods’ leadership team comprises veterans of the food, biotech and consumer goods industries. Dr. Rivera was joined in 2022 by Chief Technology Officer Jonathan Cheng, who brings experience in industrial fermentation from previous roles at leading biotech firms. Guided by a mission to bring sustainable, high‐performance ingredients to market, the executive team continues to invest in R&D, strategic partnerships and capacity expansion to support the accelerating shift toward plant-based and alternative proteins.
AI Generated. May Contain Errors.
Free BRLS Stock Alerts